Fundraise

Enlivex raises $7.5M in staggered share offering priced above market

What's the deal? Enlivex Therapeutics (Nasdaq: ENLV) has agreed to sell $7.5 million of ordinary shares and warrants in a registered direct offering priced at $1.315 per share — a 10.5% premium to its November 13 Nasdaq closing price. The Nes-Ziona, Israel-based company describes itself as "a quality longevity company powered by a prediction markets treasury."

How it's structured: Investors will buy $500,000 of securities at an initial closing around November 17, then commit to ten monthly closings of $700,000 each from December 2026 through September 2027. Payment may be made in US dollars, USDT, or a combination.

What's the money for? Enlivex intends to use net proceeds for clinical, regulatory, manufacturing, and research activities; potential acquisitions and in-licensing; and general corporate purposes. Accompanying warrants, exercisable at $1.578 per share over three years, could add roughly $9 million if exercised in full — though the company warns there is no assurance that will happen.

No middleman: The offering is being made directly by the company, without a placement agent or underwriter, so no placement agent fees apply. The shares are offered under a shelf registration that became effective in May 2025.

Why now? The raise follows a major strategic shift. After a $212 million private placement in late 2025, Enlivex pivoted from clinical-stage immunotherapy toward a RAIN-token treasury strategy, while continuing to develop its Allocetra therapy.

What could go wrong? Some subsequent closings may be delayed pending shareholder approval to increase authorised share capital, or if the company's prospectus is unavailable. Enlivex also raised $21 million in convertible debt in March 2026 and later terminated a proposed token-paid share placement to the Rain Foundation — a reminder that planned financings have not always proceeded.

The signal: At $7.5 million spread across a year of monthly tranches, this is a modest, drip-fed raise against the backdrop of far larger commitments. It adds to a pattern of ongoing financing and potential dilution as Enlivex straddles drug development and a crypto-treasury bet.

Read more: marketscreener.com

Image credit: Generated with Gemini

More top stories